Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

1

Ixazomib, lisaftoclax, and dexamethasone (ILD) combination therapy effectively achieved minimal residual disease (MRD) negativity in two patients with ultra-high-risk multiple myeloma.
2

The ILD regimen was administered orally and demonstrated durable disease control following CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
3

Ixazomib is a reversible proteasome inhibitor, while lisaftoclax is a selective BCL-2 inhibitor, both contributing to the efficacy of the ILD maintenance therapy.
4

Patients with ultra-high-risk multiple myeloma face poor prognosis and limited treatment options, highlighting the need for effective maintenance therapies post-CAR-T.
5

The study suggests that the ILD combination therapy may provide a promising new option for patients with high-risk characteristics in multiple myeloma.

1